WallStreetZenWallStreetZen

NASDAQ: ABOS
Acumen Pharmaceuticals Inc Earnings & Revenue

ABOS earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$45.0M
Current Profit Margin
0%

ABOS Return on Equity

Current Company
-23.4%
Current Industry
-18%
Current Market
30.8%
ABOS's Return on Equity (-23.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ABOS announces earnings.

ABOS Return on Assets

Current Company
-22.5%
Current Industry
0.9%
ABOS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABOS Return on Capital Employed

Current Company
-25.15%
Current Industry
14.1%

ABOS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABOS$0.00-$44.85M-$45.03MN/AN/A
LMNL$394.85k$3.74M$3.71M-18.81%-85.98%
PSTX$139.40M-$31.64M-$44.79M+326.65%N/A
ALT-$79.00k-$86.29M-$85.36MN/AN/A
CTXR$0.00-$29.92M-$30.97MN/AN/A

Acumen Pharmaceuticals Earnings & Revenue FAQ

What were ABOS's earnings last quarter?

On Invalid Date, Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q1 2023 earnings per share (EPS) of -$0.28, up 21.74% year over year. Total Acumen Pharmaceuticals earnings for the quarter were -$11.31 million. In the same quarter last year, Acumen Pharmaceuticals's earnings per share (EPS) was -$0.23.

If you're new to stock investing, here's how to buy Acumen Pharmaceuticals stock.

What was ABOS's earnings growth in the past year?

As of Q2 2023, Acumen Pharmaceuticals's earnings has grown year over year. Acumen Pharmaceuticals's earnings in the past year totalled -$45.03 million.

What was ABOS's revenue last quarter?

On Invalid Date, Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Acumen Pharmaceuticals's revenue was $0.00.

What was ABOS's revenue growth in the past year?

As of Q2 2023, Acumen Pharmaceuticals's revenue has grown null year over year. Acumen Pharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.